1
|
Rizvi SF, Zhang L, Zhang H, Fang Q. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic. ACS Pharmacol Transl Sci 2024; 7:309-334. [PMID: 38357281 PMCID: PMC10863443 DOI: 10.1021/acsptsci.3c00269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 12/23/2023] [Accepted: 12/27/2023] [Indexed: 02/16/2024]
Abstract
The emergence of peptide-drug conjugates (PDCs) that utilize target-oriented peptide moieties as carriers of cytotoxic payloads, interconnected with various cleavable/noncleavable linkers, resulted in the key-foundation of the new era of targeted therapeutics. They are capable of retaining the integrity of conjugates in the blood circulatory system as well as releasing the drugs at the tumor microenvironment. Other valuable advantages are specificity and selectivity toward targeted-receptors, higher penetration ability, and drug-loading capacity, making them a suitable candidate to play their vital role as promising carrier agents. In this review, we summarized the types of cell-targeting (CTPs) and cell-penetrating peptides (CPPs) that have broad applications in the advancement of targeted drug-delivery systems (DDS). Moreover, the techniques to overcome the limitations of peptide-chemistry for their extensive implementation to construct the PDCs. Besides this, the diversified breakthrough of linker chemistry, and ample knowledge of various cytotoxic payloads used in PDCs in recent years, as well as the mechanism of action of PDCs was critically discussed. The principal aim is to provide scattered and diversified knowledge in one place and to help researchers understand the pinching knots in the science of PDC development, also their progression toward a bright future for PDCs as novel theranostics in clinical practice.
Collapse
Affiliation(s)
- Syed Faheem
Askari Rizvi
- Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Pathology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu P.R. China
- State
Key Laboratory of Applied Organic Chemistry, College of Chemistry
and Chemical Engineering, Lanzhou University, Lanzhou, 730000, Gansu P.R. China
- Institute
of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, 54000, Punjab Pakistan
| | - Linjie Zhang
- State
Key Laboratory of Applied Organic Chemistry, College of Chemistry
and Chemical Engineering, Lanzhou University, Lanzhou, 730000, Gansu P.R. China
| | - Haixia Zhang
- State
Key Laboratory of Applied Organic Chemistry, College of Chemistry
and Chemical Engineering, Lanzhou University, Lanzhou, 730000, Gansu P.R. China
| | - Quan Fang
- Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Pathology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, Gansu P.R. China
| |
Collapse
|
2
|
Sidorenko GV, Miroslavov AE, Tyupina MY. Technetium(I) carbonyl complexes for nuclear medicine: Coordination-chemical aspect. Coord Chem Rev 2023. [DOI: 10.1016/j.ccr.2022.214911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
3
|
Kurth J, Potratz M, Heuschkel M, Krause BJ, Schwarzenböck SM. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals. Nuklearmedizin 2022; 61:247-261. [PMID: 35668669 DOI: 10.1055/a-1759-4189] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Addressing molecular targets, that are overexpressed by various tumor entities, using radiolabeled molecules for a combined diagnostic and therapeutic (theranostic) approach is of increasing interest in oncology. The gastrin-releasing peptide receptor (GRPr), which is part of the bombesin family, has shown to be overexpressed in a variety of tumors, therefore, serving as a promising target for those theranostic applications. A large amount of differently radiolabeled bombesin derivatives addressing the GRPr have been evaluated in the preclinical as well as clinical setting showing fast blood clearance and urinary excretion with selective GRPr-binding. Most of the available studies on GRPr-targeted imaging and therapy have evaluated the theranostic approach in prostate and breast cancer applying bombesin derivatives tagged with the predominantly used theranostic pair of 68Ga/177Lu which is the focus of this review.
Collapse
Affiliation(s)
- Jens Kurth
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany
| | - Madlin Potratz
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany
| | - Martin Heuschkel
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany
| | - Bernd J Krause
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany
| | | |
Collapse
|
4
|
Kaihani S, Sadeghzadeh N. Study of the 99m Tc-labeling conditions of 6-hydrazinonicotinamide-conjugated peptides from a new perspective: Introduction to the term radio-stoichiometry. J Labelled Comp Radiopharm 2020; 63:582-596. [PMID: 32997359 DOI: 10.1002/jlcr.3883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 07/27/2020] [Accepted: 09/20/2020] [Indexed: 11/07/2022]
Abstract
Specific tumor uptake of peptide radiopharmaceuticals depends on tumor binding affinity and their radiochemical purity. Several important parameters that influence the 99m Tc-labeling and consequently the radiochemical purity of 6-hydrazinonicotinamide (HYNIC)-conjugated peptide are radionuclide activity, the amount of peptide, the amount of coligands, and the amount of reducing agents (stannous ion). In this review article, we have attempted studying these parameters in the HYNIC-conjugated peptides (somatostatin, cholecystokinin/gastrin, bombesin, and RGD analogs) from a new perspective to obtain most used and optimized radio-stoichiometric relationships. One of the most important results in this review is that for 99m Tc-labeling of HYNIC-conjugated peptides, it is better to consider the most calculated mole ratio between technetium-99m and the peptide (mole ratio of technetium-99m to the peptide 1:200-400). The statistical results also show that among these 99m Tc-labeled peptides, the most used and favorable coligand is tricine/EDDA with two to one (2:1) mole ratio. These optimized radio-stoichiometric relationships, favorable coligand mole ratio, and applicable radiolabeling points can greatly improve the labeling process of the HYNIC-conjugated peptides, by reducing trial and error, increasing specific activity, and saving materials.
Collapse
Affiliation(s)
- Sajad Kaihani
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
- Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Nourollah Sadeghzadeh
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
5
|
Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020; 8:571. [PMID: 32733853 PMCID: PMC7359416 DOI: 10.3389/fchem.2020.00571] [Citation(s) in RCA: 132] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 06/03/2020] [Indexed: 12/15/2022] Open
Abstract
Cancer became recently the leading cause of death in industrialized countries. Even though standard treatments achieve significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface receptors, which bind peptides are frequently overexpressed on cancer cells and can therefore be considered as promising targets for selective tumor therapy. In this review, the benefits of peptides as tumor homing agents are presented and an overview of the most commonly addressed peptide receptors is given. A special focus was set on the bombesin receptor family and the neuropeptide Y receptor family. In the second part, the specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures as an essential component of PDC are outlined. Furthermore, different drug cargos are presented including classical and recent toxic agents as well as radionuclides for diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy as advanced targeted cancer therapy is introduced and past and recent developments are reviewed.
Collapse
Affiliation(s)
- Paul Hoppenz
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | - Sylvia Els-Heindl
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | | |
Collapse
|
6
|
Farahani AM, Maleki F, Sadeghzadeh N. The Influence of Different Spacers on Biological Profile of Peptide Radiopharmaceuticals for Diagnosis and Therapy of Human Cancers. Anticancer Agents Med Chem 2020; 20:402-416. [PMID: 31889492 DOI: 10.2174/1871520620666191231161227] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 10/07/2019] [Accepted: 12/12/2019] [Indexed: 12/26/2022]
Abstract
BACKGROUND Cancer is the leading cause of death worldwide. Early detection can reduce the disadvantageous effects of diseases and the mortality in cancer. Nuclear medicine is a powerful tool that has the ability to diagnose malignancy without harming normal tissues. In recent years, radiolabeled peptides have been investigated as potent agents for cancer detection. Therefore, it is necessary to modify radiopeptides in order to achieve more effective agents. OBJECTIVE This review describes modifications in the structure of radioconjugates with spacers who have improved the specificity and sensitivity of the peptides that are used in oncologic diagnosis and therapy. METHODS To improve the biological activity, researchers have conjugated these peptide analogs to different spacers and bifunctional chelators. Many spacers of different kinds, such as hydrocarbon chain, amino acid sequence, and poly (ethyleneglycol) were introduced in order to modify the pharmacokinetic properties of these biomolecules. RESULTS Different spacers have been applied to develop radiolabeled peptides as potential tracers in nuclear medicine. Spacers with different charge and hydrophilicity affect the characteristics of peptide conjugate. For example, the complex with uncharged and hydrophobic spacers leads to increased liver uptake, while the composition with positively charged spacers results in high kidney retention. Therefore, the pharmacokinetics of radio complexes correlates to the structure and total charge of the conjugates. CONCLUSION Radio imaging technology has been successfully applied to detect a tumor in the earliest stage. For this purpose, the assessment of useful agents to diagnose the lesion is necessary. Developing peptide radiopharmaceuticals using spacers can improve in vitro and in vivo behavior of radiotracers leading to better noninvasive detection and monitoring of tumor growth.
Collapse
Affiliation(s)
- Arezou M Farahani
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran.,Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Fariba Maleki
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran.,Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Nourollah Sadeghzadeh
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran
| |
Collapse
|
7
|
Rezazadeh F, Sadeghzadeh N. Tumor targeting with 99m Tc radiolabeled peptides: Clinical application and recent development. Chem Biol Drug Des 2018; 93:205-221. [PMID: 30299570 DOI: 10.1111/cbdd.13413] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 08/19/2018] [Accepted: 09/23/2018] [Indexed: 01/16/2023]
Abstract
Targeting overexpressed receptors on the cancer cells with radiolabeled peptides has become very important in nuclear oncology in the recent years. Peptides are small and have easy preparation and easy radiolabeling protocol with no side-effect and toxicity. These properties made them a valuable tool for tumor targeting. Based on the successful imaging of neuroendocrine tumors with 111 In-octreotide, other receptor-targeting peptides such as bombesin (BBN), cholecystokinin/gastrin analogues, neurotensin analogues, glucagon-like peptide-1, and RGD peptides are currently under development or undergoing clinical trials. The most frequently used radionuclides for tumor imaging are 99m Tc and 111 In for single-photon emission computed tomography and 68 Ga and 18 F for positron emission tomography imaging. This review presents some of the 99m Tc-labeled peptides, with regard to their potential for radionuclide imaging of tumors in clinical and preclinical application.
Collapse
Affiliation(s)
- Farzaneh Rezazadeh
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.,Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
| | - Nourollah Sadeghzadeh
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
8
|
Simpson EJ, Gobbo P, Bononi FC, Murrell E, Workentin MS, Luyt LG. Bombesin-functionalized water-soluble gold nanoparticles for targeting prostate cancer. ACTA ACUST UNITED AC 2017. [DOI: 10.1002/jin2.33] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Emily J. Simpson
- Western University Chemistry; 1151 Richmond Street London Ontario N6A 5B7 Canada
| | - Pierangelo Gobbo
- Western University Chemistry; 1151 Richmond Street London Ontario N6A 5B7 Canada
| | - Fernanda C. Bononi
- Western University Chemistry; 1151 Richmond Street London Ontario N6A 5B7 Canada
| | - Emily Murrell
- Western University Chemistry; 1151 Richmond Street London Ontario N6A 5B7 Canada
| | - Mark S. Workentin
- Western University Chemistry; 1151 Richmond Street London Ontario N6A 5B7 Canada
| | - Leonard G. Luyt
- Western University Chemistry; 1151 Richmond Street London Ontario N6A 5B7 Canada
- London Regional Cancer Program; Western University Oncology; 790 Commissioners Rd. E London Ontario N6A 4L6 Canada
| |
Collapse
|
9
|
Raaymakers C, Verbrugghe E, Hernot S, Hellebuyck T, Betti C, Peleman C, Claeys M, Bert W, Caveliers V, Ballet S, Martel A, Pasmans F, Roelants K. Antimicrobial peptides in frog poisons constitute a molecular toxin delivery system against predators. Nat Commun 2017; 8:1495. [PMID: 29138448 PMCID: PMC5686178 DOI: 10.1038/s41467-017-01710-1] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 10/10/2017] [Indexed: 01/08/2023] Open
Abstract
Animals using toxic peptides and proteins for predation or defense typically depend on specialized morphological structures, like fangs, spines, or a stinger, for effective intoxication. Here we show that amphibian poisons instead incorporate their own molecular system for toxin delivery to attacking predators. Skin-secreted peptides, generally considered part of the amphibian immune system, permeabilize oral epithelial tissue and enable fast access of cosecreted toxins to the predator's bloodstream and organs. This absorption-enhancing system exists in at least three distantly related frog lineages and is likely to be a widespread adaptation, determining the outcome of predator-prey encounters in hundreds of species.
Collapse
Affiliation(s)
- Constantijn Raaymakers
- Amphibian Evolution Lab, Biology Department, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Elsene, Belgium.,Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium
| | - Elin Verbrugghe
- Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium
| | - Sophie Hernot
- Department of Nuclear Medicine, UZ Brussel and In vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Jette, Belgium
| | - Tom Hellebuyck
- Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium
| | - Cecilia Betti
- Research Group of Organic Chemistry, Department of Chemistry and Department of Bio-engineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Elsene, Belgium
| | - Cindy Peleman
- Department of Nuclear Medicine, UZ Brussel and In vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Jette, Belgium
| | - Myriam Claeys
- Department of Biology, Nematology Research Unit, Faculty of Science, Ghent University, 9000, Ghent, Belgium
| | - Wim Bert
- Department of Biology, Nematology Research Unit, Faculty of Science, Ghent University, 9000, Ghent, Belgium
| | - Vicky Caveliers
- Department of Nuclear Medicine, UZ Brussel and In vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Jette, Belgium
| | - Steven Ballet
- Research Group of Organic Chemistry, Department of Chemistry and Department of Bio-engineering Sciences, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Elsene, Belgium
| | - An Martel
- Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium
| | - Frank Pasmans
- Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium
| | - Kim Roelants
- Amphibian Evolution Lab, Biology Department, Vrije Universiteit Brussel, Pleinlaan 2, 1050, Elsene, Belgium.
| |
Collapse
|
10
|
Charron CL, Hickey JL, Nsiama TK, Cruickshank DR, Turnbull WL, Luyt LG. Molecular imaging probes derived from natural peptides. Nat Prod Rep 2017; 33:761-800. [PMID: 26911790 DOI: 10.1039/c5np00083a] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Covering: up to the end of 2015.Peptides are naturally occurring compounds that play an important role in all living systems and are responsible for a range of essential functions. Peptide receptors have been implicated in disease states such as oncology, metabolic disorders and cardiovascular disease. Therefore, natural peptides have been exploited as diagnostic and therapeutic agents due to the unique target specificity for their endogenous receptors. This review discusses a variety of natural peptides highlighting their discovery, endogenous receptors, as well as their derivatization to create molecular imaging agents, with an emphasis on the design of radiolabelled peptides. This review also highlights methods for discovering new and novel peptides when knowledge of specific targets and endogenous ligands are not available.
Collapse
Affiliation(s)
- C L Charron
- Department of Chemistry, The University of Western Ontario, London, Canada.
| | - J L Hickey
- Department of Chemistry, The University of Western Ontario, London, Canada.
| | - T K Nsiama
- London Regional Cancer Program, Lawson Health Research Institute, London, Canada
| | - D R Cruickshank
- Department of Chemistry, The University of Western Ontario, London, Canada.
| | - W L Turnbull
- Department of Chemistry, The University of Western Ontario, London, Canada.
| | - L G Luyt
- Department of Chemistry, The University of Western Ontario, London, Canada. and Departments of Oncology and Medical Imaging, The University of Western Ontario, London, Canada and London Regional Cancer Program, Lawson Health Research Institute, London, Canada
| |
Collapse
|
11
|
Mansour N, Dumulon-Perreault V, Ait-Mohand S, Paquette M, Lecomte R, Guérin B. Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [64Cu]Cu/NOTA peptide-based gastrin-releasing peptide receptors antagonists. J Labelled Comp Radiopharm 2017; 60:200-212. [DOI: 10.1002/jlcr.3491] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2016] [Revised: 01/12/2017] [Accepted: 01/24/2017] [Indexed: 12/25/2022]
Affiliation(s)
- Nematallah Mansour
- Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences; Université de Sherbrooke and Sherbrooke Molecular Imaging Centre, Centre de recherche du CHUS (CRCHUS); Sherbrooke Canada
| | - Véronique Dumulon-Perreault
- Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences; Université de Sherbrooke and Sherbrooke Molecular Imaging Centre, Centre de recherche du CHUS (CRCHUS); Sherbrooke Canada
| | - Samia Ait-Mohand
- Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences; Université de Sherbrooke and Sherbrooke Molecular Imaging Centre, Centre de recherche du CHUS (CRCHUS); Sherbrooke Canada
| | - Michel Paquette
- Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences; Université de Sherbrooke and Sherbrooke Molecular Imaging Centre, Centre de recherche du CHUS (CRCHUS); Sherbrooke Canada
| | - Roger Lecomte
- Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences; Université de Sherbrooke and Sherbrooke Molecular Imaging Centre, Centre de recherche du CHUS (CRCHUS); Sherbrooke Canada
| | - Brigitte Guérin
- Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences; Université de Sherbrooke and Sherbrooke Molecular Imaging Centre, Centre de recherche du CHUS (CRCHUS); Sherbrooke Canada
| |
Collapse
|
12
|
Feng Y, Phelps TE, Carroll V, Gallazzi F, Sieckman G, Hoffman TJ, Barnes CL, Ketring AR, Hennkens HM, Jurisson SS. Chemistry and radiochemistry of As, Re and Rh isotopes relevant to radiopharmaceutical applications: high specific activity radionuclides for imaging and treatment. Dalton Trans 2017; 46:14677-14690. [DOI: 10.1039/c7dt02407j] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Advances in production, separation, target recovery, and chelation chemistry of high specific activity radionuclides will promote new theranostic agent development.
Collapse
Affiliation(s)
- Yutian Feng
- Department of Chemistry
- University of Missouri
- Columbia
- USA
| | - Tim E. Phelps
- Department of Chemistry
- University of Missouri
- Columbia
- USA
| | | | - Fabio Gallazzi
- Structural Biology Core
- University of Missouri
- Columbia
- USA
| | - Gary Sieckman
- Research Division
- Harry S. Truman Memorial Veterans’ Hospital
- Columbia
- USA
| | | | | | - Alan R. Ketring
- University of Missouri Research Reactor Center (MURR)
- University of Missouri
- Columbia
- USA
| | - Heather M. Hennkens
- University of Missouri Research Reactor Center (MURR)
- University of Missouri
- Columbia
- USA
| | | |
Collapse
|
13
|
Ferreira CDA, Fuscaldi LL, Townsend DM, Rubello D, Barros ALBD. Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed Pharmacother 2016; 87:58-72. [PMID: 28040598 DOI: 10.1016/j.biopha.2016.12.083] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 12/15/2016] [Accepted: 12/20/2016] [Indexed: 01/04/2023] Open
Abstract
Despite efforts, cancer is still one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths each year, according to the World Health Organization. Among the strategies to reduce cancer progression and improving its management, implementing early detection technologies is crucial. Based on the fact that several types of cancer cells overexpress surface receptors, small molecule ligands, such as peptides, have been developed to allow tumor identification at earlier stages. Allied with imaging techniques such as PET and SPECT, radiolabeled peptides play a pivotal role in nuclear medicine. Bombesin, a peptide of 14 amino acids, is an amphibian homolog to the mammalian gastrin-releasing peptide (GRP), that has been extensively studied as a targeting ligand for diagnosis and therapy of GRP positive tumors, such as breast, pancreas, lungs and prostate cancers. In this context, herein we provide a review of reported bombesin derivatives radiolabeled with a multitude of radioactive isotopes for diagnostic purposes in the preclinical setting. Moreover, since animal models are highly relevant for assessing the potential of clinical translation of this radiopeptides, a brief report of the currently used GRP-positive tumor-bearing animal models is described.
Collapse
Affiliation(s)
| | - Leonardo Lima Fuscaldi
- Faculty of Pharmacy, Federal University of Minas Gerais, Av. Antônio Carlos, 6627, 31270-901, Belo Horizonte, Minas Gerais, Brazil
| | - Danyelle M Townsend
- Department of Drug Discovery and Pharmaceutical Sciences, Medical University of South Carolina, USA
| | - Domenico Rubello
- Department of Nuclear Medicine, Radiology, NeuroRadiology, Medical Physics, Clinical Laboratory, Microbiology, Pathology, Santa Maria della Misericordia Hospital, Rovigo, Italy.
| | - André Luís Branco de Barros
- Faculty of Pharmacy, Federal University of Minas Gerais, Av. Antônio Carlos, 6627, 31270-901, Belo Horizonte, Minas Gerais, Brazil
| |
Collapse
|
14
|
De Tommaso G, Celentano V, Malgieri G, Fattorusso R, Romanelli A, D'Andrea LD, Iuliano M, Isernia C. fac-[Re(H2O)3(CO)3]+Complexed with Histidine and Imidazole in Aqueous Solution: Speciation, Affinity and Binding Features. ChemistrySelect 2016. [DOI: 10.1002/slct.201600817] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Gaetano De Tommaso
- Department of Chemical Sciences; University of Naples “Federico II”; Cupa Nuova Cintia 21- 80126 Naples ITALY
| | - Veronica Celentano
- Institute of Biostructure and Bioimaging CNR; Via Mezzocannone 16-80134 Naples ITALY
| | - Gaetano Malgieri
- Department of Environmental, Biological and Pharmaceutical Sciences; Technologies, Second University of Naples; Via Vivaldi 43-81100 Caserta Italy
| | - Roberto Fattorusso
- Department of Environmental, Biological and Pharmaceutical Sciences; Technologies, Second University of Naples; Via Vivaldi 43-81100 Caserta Italy
- Interuniversity Research Centre on Bioactive Peptides; Via Mezzocannone 16-80134 Naples Italy
| | - Alessandra Romanelli
- Department of Pharmacy; University of Naples “Federico II”; Via Mezzocannone 16-80134 Naples Italy
- Interuniversity Research Centre on Bioactive Peptides; Via Mezzocannone 16-80134 Naples Italy
| | - Luca Domenico D'Andrea
- Institute of Biostructure and Bioimaging CNR; Via Mezzocannone 16-80134 Naples ITALY
- Interuniversity Research Centre on Bioactive Peptides; Via Mezzocannone 16-80134 Naples Italy
| | - Mauro Iuliano
- Department of Chemical Sciences; University of Naples “Federico II”; Cupa Nuova Cintia 21- 80126 Naples ITALY
| | - Carla Isernia
- Department of Environmental, Biological and Pharmaceutical Sciences; Technologies, Second University of Naples; Via Vivaldi 43-81100 Caserta Italy
- Interuniversity Research Centre on Bioactive Peptides; Via Mezzocannone 16-80134 Naples Italy
| |
Collapse
|
15
|
Comparison of estimated human effective dose of 67Ga- and 99mTc-labeled bombesin based on distribution data in mice. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-3995-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
KIM MINHWAN, PARK JIAE, WOO SANGKEUN, LEE KYOCHUL, AN GWANGIL, KIM BYOUNGSOO, KIM KWANGIL, LEE TAESUP, KIM CHANWHA, KIM KYEONGMIN, KANG JOOHYUN, LEE YONGJIN. Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model. Int J Oncol 2015; 46:1159-68. [PMID: 25586565 DOI: 10.3892/ijo.2015.2832] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 12/23/2014] [Indexed: 11/06/2022] Open
|
17
|
Czaplewska JA, Theil F, Altuntas E, Niksch T, Freesmeyer M, Happ B, Pretzel D, Schäfer H, Obata M, Yano S, Schubert US, Gottschaldt M. Glycoconjugated Rhenium(I) and 99m-Technetium(I) Carbonyl Complexes from Pyridyltriazole Ligands Obtained by “Click Chemistry”. Eur J Inorg Chem 2014. [DOI: 10.1002/ejic.201402881] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
18
|
Hickey JL, Simpson EJ, Hou J, Luyt LG. An Integrated Imaging Probe Design: The Synthesis of99mTc/Re-Containing Macrocyclic Peptide Scaffolds. Chemistry 2014; 21:568-78. [DOI: 10.1002/chem.201404774] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Indexed: 11/11/2022]
|
19
|
Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the 99mTc core. Bioorg Med Chem 2013; 21:6699-707. [DOI: 10.1016/j.bmc.2013.08.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Revised: 07/12/2013] [Accepted: 08/05/2013] [Indexed: 11/19/2022]
|
20
|
Sturzu A, Sheikh S, Echner H, Nägele T, Deeg M, Amin B, Schwentner C, Horger M, Ernemann U, Heckl S. Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging. Invest New Drugs 2013; 32:37-46. [DOI: 10.1007/s10637-013-9975-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 05/08/2013] [Indexed: 10/26/2022]
|
21
|
Sadeghzadeh N, Ahmadzadeh M, Erfani M. Evaluation of a new radiolabeled bombesin derivative with 99mTc as potential targeted tumor imaging agent. J Radioanal Nucl Chem 2013. [PMID: 26224936 PMCID: PMC4513902 DOI: 10.1007/s10967-013-2464-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Gastrin-releasing peptide (GRP) receptors are over-expressed in various human tumor including breast and prostate which can be targeted with bombesin for diagnosis and targeted therapy. High abdominal accumulation and the poor in vivo stability of radiolabeled bombesin analogues may represent a limitation for diagnostic imaging and targeted therapy. In this study a new bombesin derivative was labeled with 99mTc via HYNIC and tricine as a coligand and investigated further. The peptide HYNIC conjugate was synthesized on a solid phase using Fmoc strategy. Labeling with 99mTc was performed at 100 °C for 10 min and radiochemical analysis involved ITLC and HPLC methods. The stability of radiopeptide was checked in the presence of human serum at 37 °C up to 24 h. Internalization was studied with the human GRP receptor cell line PC-3. The Biodistribution was studied in mice. Labeling yield of >98 % was obtained to correspond a specific activity of ~80.9 GBq/μmol. Radioconjugate internalization into PC-3 cells was high and specific (15.6 ± 1.9 % at 4 h). A high and specific uptake in GRP-receptor-positive organs such as mouse tumor and pancreas (2.11 ± 0.18 and 1.78 ± 0.09 % ID/g after 1 h respectively) was also determined.
Collapse
Affiliation(s)
- N Sadeghzadeh
- Faculty of Pharmacy, Department of Radiopharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - M Ahmadzadeh
- Faculty of Pharmacy, Department of Radiopharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - M Erfani
- Nuclear Science Research School, Nuclear Science & Technology Research Institute (NSTRI), Atomic Energy Organization of Iran, Tehran, Iran
| |
Collapse
|
22
|
Varshney R, Hazari PP, Fernandez P, Schulz J, Allard M, Mishra AK. (68)Ga-labeled bombesin analogs for receptor-mediated imaging. Recent Results Cancer Res 2013; 194:221-256. [PMID: 22918762 DOI: 10.1007/978-3-642-27994-2_12] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Targeted receptor-mediated imaging techniques have become crucial tools in present targeted diagnosis and radiotherapy as they provide accurate and specific diagnosis of disease information. Peptide-based pharmaceuticals are gaining popularity, and there has been vast interest in developing (68)Ga-labeled bombesin (Bn) analogs. The gastrin-releasing peptide (GRP) family and its Bn analog have been implicated in the biology of several human cancers. The three bombesin receptors GRP, NMB, and BRS-3 receptor are most frequently ectopically expressed by common, important malignancies. The low expression of Bn/GRP receptors in normal tissue and relatively high expression in a variety of human tumors can be of biological importance and form a molecular basis for Bn/GRP receptor-mediated imaging. To develop a Bn-like peptide with favorable tumor targeting and pharmacokinetic characteristics for possible clinical use, several modifications in the Bn-like peptides, such as the use of a variety of chelating agents, i.e., acyclic and macrocyclic agents with different spacer groups and with different metal ions (gallium), have been performed in recent years without significant disturbance of the vital binding scaffold. The favorable physical properties of (68)Ga, i.e., short half-life, and the fast localization of small peptides make this an ideal combination to study receptor-mediated imaging in patients.
Collapse
|
23
|
Sagnou M, Tzanopoulou S, Raptopoulou CP, Psycharis V, Braband H, Alberto R, Pirmettis IC, Papadopoulos M, Pelecanou M. A Phenylbenzothiazole Conjugate with the Tricarbonyl fac-[M(I)(CO)3]+ (M = Re, 99Tc, 99mTc) Core for Imaging of β-Amyloid Plaques. Eur J Inorg Chem 2012. [DOI: 10.1002/ejic.201200450] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
24
|
Laverman P, Sosabowski JK, Boerman OC, Oyen WJG. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging 2012; 39 Suppl 1:S78-92. [PMID: 22388627 PMCID: PMC3304069 DOI: 10.1007/s00259-011-2014-7] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Radiolabelled receptor-binding peptides targeting receptors (over)expressed on tumour cells are widely under investigation for tumour diagnosis and therapy. The concept of using radiolabelled receptor-binding peptides to target receptor-expressing tissues in vivo has stimulated a large body of research in nuclear medicine. The 111In-labelled somatostatin analogue octreotide (OctreoScan™) is the most successful radiopeptide for tumour imaging, and was the first to be approved for diagnostic use. Based on the success of these studies, other receptor-targeting peptides such as cholecystokinin/gastrin analogues, glucagon-like peptide-1, bombesin (BN), chemokine receptor CXCR4 targeting peptides, and RGD peptides are currently under development or undergoing clinical trials. In this review, we discuss some of these peptides and their analogues, with regard to their potential for radionuclide imaging of tumours.
Collapse
Affiliation(s)
- Peter Laverman
- Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
| | | | | | | |
Collapse
|
25
|
Liolios CC, Fragogeorgi EA, Zikos C, Loudos G, Xanthopoulos S, Bouziotis P, Paravatou-Petsotas M, Livaniou E, Varvarigou AD, Sivolapenko GB. Structural modifications of ⁹⁹mTc-labelled bombesin-like peptides for optimizing pharmacokinetics in prostate tumor targeting. Int J Pharm 2012; 430:1-17. [PMID: 22459664 DOI: 10.1016/j.ijpharm.2012.02.049] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Revised: 02/24/2012] [Accepted: 02/26/2012] [Indexed: 10/28/2022]
Abstract
PURPOSE The main goal of the present study was to investigate the importance of the addition of a positively charged aa in the naturally occurring bombesin (BN) peptide for its utilization as radiodiagnostic agent, taking into consideration the biodistribution profile, the pharmacokinetic characteristics and the tumor targeting ability. METHODS Two BN-derivatives of the general structure [M-chelator]-(spacer)-BN(2-14)-NH(2), where M: (99m)Tc or (185/187)Re, chelator: Gly-Gly-Cys-, spacer: -(arginine)(3)-, M-BN-A; spacer: -(ornithine)(3)-, M-BN-O; have been prepared and evaluated as tumor imaging agents. RESULTS The peptides under study presented high radiolabelling efficiency (>98%), significant stability in human plasma (>60% intact radiolabelled peptide after 1h incubation) and comparable receptor binding affinity with the standard [(125)I-Tyr(4)]-BN. Their internalization rates in the prostate cancer PC-3 cells differed, although the amount of internalized peptide was the same. The biodistribution and the dynamic γ-camera imaging studies in normal and PC-3 tumor-bearing SCID mice have shown significant tumor uptake, combined with fast blood clearance, through the urinary pathway. CONCLUSION The addition of the charged aa spacer in the BN structure was advantageous for biodistribution, pharmacokinetics and tumor targeting ability, because it reduced the upper abdominal radioactivity levels and increased tumor/normal tissue contrast ratios.
Collapse
Affiliation(s)
- Christos C Liolios
- Institute of Radioisotopes & Radiodiagnostic Products, NCSR Demokritos, 15310 Athens, Greece.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Hernández-Cairo A, Perera-Pintado A, Prats-Capote A, Batista-Cuellar J, Casacó-Santana C. Comparative Study of the Biodistribution of 99mTc-HYNIC-Lys3-Bombesin Obtained With the EDDA/Tricine and AN/Tricine as Coligands. Rev Esp Med Nucl Imagen Mol 2012. [DOI: 10.1016/j.remnie.2011.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Hernández-Cairo A, Perera-Pintado A, Prats-Capote A, Batista-Cuellar JF, Casacó-Santana C. [Comparative study of the biodistribution of (99m)Tc-HYNIC-Lys3-Bombesin obtained with the EDDA/tricine and NA/tricine as coligands]. Rev Esp Med Nucl Imagen Mol 2012; 31:61-5. [PMID: 22305264 DOI: 10.1016/j.remn.2011.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2011] [Revised: 09/22/2011] [Accepted: 09/30/2011] [Indexed: 11/24/2022]
Abstract
The aim of present investigation was to evaluate biodistribution in healthy animals and in tumor models of the radiopharmaceuticals (99m)Tc-EDDA/tricine-HYNIC-Lys3-Bombesin (HYNIC-Lys3-BN) and (99m)Tc-NA/tricine-HYNIC-Lys3-BN. Biodistribution and pharmacokinetics were carried out over 24 hours. To do so, 24 healthy Wistar rats were used and were administered 37.0 ± 0.8 MBq/rat of each radiopharmaceutical. For the tumor model study, 20 CD-1 nude mice were used and prostate tumors (PC3) were implanted in all the mice. Ten days later, tumor volumes were calculated and 40.00 ± 0.04 MBq/mice of each radiopharmaceutical were injected. Both showed high radiochemical purity: 98.08 ± 0.25% for EDDA/tricine product and 95.1 ± 0.3% for the conjugate with NA/tricine. Uptake of the radiopharmaceutical with NA/tricine was significantly higher in organs of the reticulo-endothelial system of healthy Wistar rats during 24h, specifically in the liver and spleen. Both labeled compounds showed no significant differences between their blood elimination half lives. Average of tumor growth was 0.93 ± 0.02 cm(3) and affinity for tumors showed a growing and specific binding of both radiopharmaceuticals, although it was significantly higher for the EDDA/tricine conjugate. This outcome made it possible to corroborate the direct relationship between the density of gastrin releasing peptide and its receptors (GRPr) and the variation of the accumulation of the radiopharmaceuticals in the tumor. Use of EDDA/tricine as coligand is more appropriate than NA/tricine for labeling of HYNIC-Lys3-BN with (99m)Tc.
Collapse
|
28
|
Steinmetz NF, Ablack AL, Hickey JL, Ablack J, Manocha B, Mymryk JS, Luyt LG, Lewis JD. Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2011; 7:1664-72. [PMID: 21520408 PMCID: PMC3163449 DOI: 10.1002/smll.201000435] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2010] [Revised: 09/27/2010] [Indexed: 05/02/2023]
Abstract
Multivalent nanoparticles have several key advantages in terms of solubility, binding avidity, and uptake, making them particularly well suited to molecular imaging applications. Herein is reported the stepwise synthesis and characterization of NIR viral nanoparticles targeted to gastrin-releasing peptide receptors that are over-expressed in human prostate cancers. The pan-bombesin analogue, [β-Ala11, Phe13, Nle14]bombesin-(7-14), is conjugated to cowpea mosaic virus particles functionalized with an NIR dye (Alexa Fluor 647) and polyethylene glycol (PEG) using the copper(I)-catalyzed azide-alkyne cycloaddition reaction. Targeting and uptake in human PC-3 prostate cells is demonstrated in vitro. Tumor homing is observed using human prostate tumor xenografts on the chicken chorioallantoic membrane model using intravital imaging. Further development of this viral nanoparticle platform may open the door to potential clinical noninvasive molecular imaging strategies.
Collapse
Affiliation(s)
| | | | | | - Jailal Ablack
- Department of Oncology, London Regional Cancer Program, 790 Commissioners Rd. E., London, Ontario N6A 4L6, Canada
| | - Bhavik Manocha
- Translational Prostate Cancer Research Group London Regional Cancer Program, Room A4-823, 790 Commissioners Rd. E., London, Ontario N6A 4L6, Canada
| | - Joe S. Mymryk
- Department of Oncology, London Regional Cancer Program, 790 Commissioners Rd. E., London, Ontario N6A 4L6, Canada
| | - Leonard G. Luyt
- Department of Chemistry University of Western Ontario London, Ontario N6A 5C1, Canada
| | | |
Collapse
|
29
|
Shirmardi SP, Gandomkar M, Maragheh MG, Shamsaei M. Preclinical Evaluation of a New Bombesin Analog for Imaging of Gastrin-Releasing Peptide Receptors. Cancer Biother Radiopharm 2011; 26:309-16. [DOI: 10.1089/cbr.2010.0912] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Seyed Pezhman Shirmardi
- Faculty of Nuclear engineering and Physics, Amirkabir University of Technology, Tehran, Iran
- Nuclear Science Research School, Nuclear Sciences and Technology Research Institute, Tehran, Iran
| | - Mostafa Gandomkar
- Nuclear Science Research School, Nuclear Sciences and Technology Research Institute, Tehran, Iran
| | | | - Mojtaba Shamsaei
- Faculty of Nuclear engineering and Physics, Amirkabir University of Technology, Tehran, Iran
| |
Collapse
|
30
|
Chiotellis A, Tsoukalas C, Pelecanou M, Pirmettis I, Papadopoulos M. New 99mTc(CO)3(NNO) complexes in the development of 5HT1A receptor imaging agents. RADIOCHIM ACTA 2011. [DOI: 10.1524/ract.2011.1835] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Abstract
In this work we report the synthesis, characterization and biological evaluation of two new neutral tricarbonyl fac-M(CO)3(NNO) (M=Re, 99mTc) derivatives of WAY-100635 as potential 99mTc agents for the in vivo imaging of 5HT1A receptors. The new pharmacophore NNO ligands are based on the picolylamine N,N-diacetic acid (PADA) ligand and their synthesis was achieved through the PADA anhydride, showing thus the applicability of this synthetic approach, developed in our laboratory, for the incorporation of bioactive amines in the PADA molecule and the development of target specific radiopharmaceuticals. The rhenium complexes were synthesized using [NEt4]2[Re(CO)3Br3] as a precursor and fully characterized by elemental analysis and spectroscopic methods. The analogous technetium-99m complexes were also prepared quantitatively using the [99mTc(CO)3(H2O)3]+ precursor and their structure corroborated by means of the rhenium complexes. The lipophilicity of the Tc complexes is in the range normally accepted for substances to be able to cross the BBB. Competition binding tests showed moderate affinity for the 5HT1A receptors, with IC50 values at the nanomolar range (30 and 116 nM). Biodistribution in healthy animals was characterized by high initial blood and liver uptake and fast blood and tissue depuration with excretion taking place mainly through the hepatobiliary system. None of the new complexes showed any significant brain uptake, suggesting that the ability of a compound to cross the BBB is determined by more factors than charge, lipophilicity and size.
Collapse
Affiliation(s)
- A. Chiotellis
- National Centre for Scientific Research “Demokritos“, Institute of Radioisotopes - Radiodiagnostic Produ, Athens, Griechenland
| | | | - M. Pelecanou
- National Centre for Scientific Research Demokritos, Institute of Biology, Athens, Griechenland
| | - I. Pirmettis
- National Centre for Scientific Research Demokritos, Institute of Radioisotopes - Radiodiagnostic Produ, Athens, Griechenland
| | - M. Papadopoulos
- National Centre for Scientific Research Demokritos, Institute of Radioisotopes - Radiodiagnostic Produ, Athens, Griechenland
| |
Collapse
|
31
|
Liu S, Chakraborty S. 99mTc-centered one-pot synthesis for preparation of 99mTc radiotracers. Dalton Trans 2011; 40:6077-86. [PMID: 21373664 DOI: 10.1039/c0dt01462a] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Nuclear medicine relies on two main imaging modalities: single photon emission computed tomography (SPECT) and positron emission tomography (PET). Radiopharmaceuticals (or radiotracers) are the blood stream of nuclear medicine for the diagnosis or therapy of diseases. Diagnostic radiotracers that are small molecules labelled with a gamma-emitter for SPECT or positron-emitter for PET provide a non-invasive method to assess the disease or disease states and monitor the therapeutic efficacy of a specific treatment regime. Over the past four decades, radiopharmaceutical research has been practising one-pot synthesis at the tracer level (10(-7)-10(-6) M). Many (99m)Tc radiotracers currently used in nuclear medicine are routinely prepared by following the basic principles of one-pot synthesis. Unlike traditional organic one-pot synthesis, which often involves the formation of multiple C-C and C-heteroatom bonds in a single step, the (99m)Tc-centered one-pot synthesis requires the formation of multiple coordination bonds between Tc and various donor atoms, such as N, O, S and P. This review will illustrate how the (99m)Tc-centered one-pot synthesis is utilized for routine preparations of different (99m)Tc radiotracers.
Collapse
Affiliation(s)
- Shuang Liu
- School of Health Sciences, Purdue University 550 Stadium Mall Drive, West Lafayette, IN 47907, USA.
| | | |
Collapse
|
32
|
Synthesis and evaluation of a new bombesin analog labeled with 99mTc as a GRP receptor imaging agent. J Radioanal Nucl Chem 2011. [DOI: 10.1007/s10967-011-0985-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Ferro-Flores G, Rivero I, Santos-Cuevas C, Sarmiento J, Arteaga de Murphy C, Ocampo-García B, García-Becerra R, Ordaz-Rosado D. Click chemistry for [99mTc(CO)3] labeling of Lys3-bombesin. Appl Radiat Isot 2010; 68:2274-8. [DOI: 10.1016/j.apradiso.2010.06.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2009] [Revised: 06/08/2010] [Accepted: 06/11/2010] [Indexed: 11/29/2022]
|
34
|
Teodoro R, Faintuch BL, Núñez EGF, Queiróz RG. Neurotensin(8-13) analogue: radiolabeling and biological evaluation using different chelators. Nucl Med Biol 2010; 38:113-20. [PMID: 21220134 DOI: 10.1016/j.nucmedbio.2010.06.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2009] [Revised: 06/01/2010] [Accepted: 06/14/2010] [Indexed: 12/28/2022]
Abstract
INTRODUCTION Several strategies on the development of radiopharmaceuticals have been employed. Bifunctional chelators seem to be a promising approach since high radiochemical yields as well as good in vitro and in vivo stability have been achieved. To date, neurotensin analogs have been radiolabeled using the (99m)Tc-carbonyl approach and none was described employing the bifunctional chelating agent technique. AIM The purpose of this study was to evaluate the radiochemical and biological behaviour of NT(8-13) analogue radiolabeled with (99m)Tc, using HYNIC and NHS-S-acetyl-MAG(3) as chelator agents. METHODS Radiolabeling, in vitro stability toward cysteine and glutathione, partition coefficient and plasma protein binding were assessed for both radioconjugates. Biodistribution in healthy Swiss mice were carried out in order to evaluate the biological behaviour of the radiocomplexes. RESULTS Radiochemical yields were higher than 97% and no apparent instability toward transchelant agents was observed for both radioconjugates. A higher lipophilic character was observed for the radioconjugate labeled via MAG(3). The chelators seem to have no effect on the percentage of the radioconjugate bound to plasma proteins. A similar biological pattern was observed for both radioconjugates. Total blood, bone and muscle values revealed a slightly slower clearance for the radiocomplex labeled via MAG(3). Moreover, a remarkable liver and intestinal uptake was observed for the radiocomplex labeled via MAG(3) even at the later time points studied. CONCLUSION The high radiochemical yields achieved and the similar in vivo pattern found for both radioconjugates make them potential candidates for imaging tumors using nuclear medicine techniques.
Collapse
Affiliation(s)
- Rodrigo Teodoro
- Center of Radiopharmacy, Institute of Energetic and Nuclear Research, Sao Paulo, SP 05508-000, Brazil.
| | | | | | | |
Collapse
|
35
|
Sadeghzadeh N, Gandomkar M, Najafi R, Shafiei M, Sadat Ebrahimi SE, Shafiee A, Larijani B. Preparation and evaluation of a new 99mTc labeled bombesin derivative for tumor imaging. J Radioanal Nucl Chem 2009. [DOI: 10.1007/s10967-009-0138-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Gourni E, Bouziotis P, Benaki D, Loudos G, Xanthopoulos S, Paravatou-Petsotas M, Mavri-Vavagianni M, Pelecanou M, Archimandritis SC, Varvarigou AD. Structural Assessment and Biological Evaluation of Two N3S Bombesin Derivatives. J Med Chem 2009; 52:4234-46. [DOI: 10.1021/jm900360d] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Eleni Gourni
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Penelope Bouziotis
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Dimitra Benaki
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - George Loudos
- Department of Medical Instruments Technology, Technological Educational Institute of Athens, Athens, Greece
| | - Stavros Xanthopoulos
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Maria Paravatou-Petsotas
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | | | - Maria Pelecanou
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Spyros C. Archimandritis
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| | - Alexandra D. Varvarigou
- Institutes of Radioisotopes—Radiodiagnostic Products and Biology, NCSR “Demokritos”, 15310 Athens, Greece
| |
Collapse
|
37
|
Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Ramírez FDM, Luna-Gutiérrez MA, Pedraza-López M, García-Becerra R, Ordaz-Rosado D. Design, preparation, in vitro and in vivo evaluation of 99mTc-N2S2-Tat(49–57)-bombesin: A target-specific hybrid radiopharmaceutical. Int J Pharm 2009; 375:75-83. [DOI: 10.1016/j.ijpharm.2009.04.018] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2008] [Revised: 04/11/2009] [Accepted: 04/14/2009] [Indexed: 10/20/2022]
|
38
|
Liu Z, Yu Z, He W, Ma S, Sun L, Wang F. In-VitroInternalization andIn-VivoTumor Uptake of Anti-EGFR Monoclonal Antibody LA22 in A549 Lung Cancer Cells and Animal Model. Cancer Biother Radiopharm 2009; 24:15-24. [DOI: 10.1089/cbr.2008.0537] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Zhaofei Liu
- Medical Isotopes Research Center, Peking University, Beijing, China
| | - Zilin Yu
- Medical Isotopes Research Center, Peking University, Beijing, China
| | - Weiwei He
- Medical Isotopes Research Center, Peking University, Beijing, China
| | - Shujun Ma
- Welson Pharmaceuticals, Inc., Ellicott City, MD
| | - Le Sun
- Welson Pharmaceuticals, Inc., Ellicott City, MD
| | - Fan Wang
- Medical Isotopes Research Center, Peking University, Beijing, China
| |
Collapse
|
39
|
Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women. Nucl Med Commun 2008; 29:741-7. [PMID: 18753829 DOI: 10.1097/mnm.0b013e3282ffb45c] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND The gastrin-releasing peptide receptor (GRP-R) is expressed in several normal human tissues and is overexpressed in various human tumors including breast, prostate, small-cell lung cancer and pancreatic cancer. Recently, 99mTc-EDDA/HYNIC-[Lys]-bombesin (99mTc-HYNIC-BN) was reported as a radiopharmaceutical with high stability in human serum, specific cell GRP-R binding and rapid cell internalization. AIM The aim of this study was to determine the biokinetics and dosimetry of 99mTc-HYNIC-BN and the feasibility of using this radiopharmaceutical to image GRP-R in four early breast cancer patients and seven healthy women. METHODS Whole-body images were acquired at 20, 90, 180 min, and 24 h after 99mTc-HYNIC-BN administration. The same regions of interest were drawn around source organs on each time frame and regions of interest were converted to activity (conjugate view counting method). The image sequence was used to extrapolate 99mTc-HYNIC-BN time-activity curves in each organ to calculate the total number of disintegrations (N) that occurred in the source regions. N data were the input for the OLINDA/EXM code to calculate internal radiation dose estimates. RESULTS 99mTc-HYNIC-BN had a rapid blood clearance with mainly renal excretion. No statistically significant differences (P>0.05) in the radiation-absorbed doses among cancer patients and healthy women were observed. The average equivalent doses (n=11) were 24.8+/-8.8 mSv (kidneys), 7.3+/-1.8 mSv (lungs), 6.5+/-4.0 mSv (breast), 2.0+/-0.3 mSv (pancreas), 1.6+/-0.3 mSv (liver), 1.2+/-0.2 mSv (ovaries), and 1.0+/-0.2 mSv (red marrow). The effective dose was 3.3+/-0.6 mSv. The images showed well-differentiated concentration of 99mTc-HYNIC-BN in cancer mammary tissue. CONCLUSION All the absorbed doses were comparable with those known for most of the 99mTc studies. 99mTc-HYNIC-BN shows high tumor uptake in breasts with malignant tumors so it is a promising imaging radiopharmaceutical to target site-specific early breast cancer. The results obtained warrant a further clinical study to determine specificity/sensibility of 99mTc-HYNIC-BN.
Collapse
|
40
|
Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008; 35:401-11. [PMID: 18482677 DOI: 10.1016/j.nucmedbio.2008.02.005] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2007] [Revised: 02/17/2008] [Accepted: 02/28/2008] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Radionuclide imaging can be a useful tool for the diagnosis of prostate cancer. Bombesin (BBN) is a molecule with high affinity for gastrin releasing peptide (GRP) receptors which are over-expressed in that tumor. This report compares (99m)Tc-HYNIC-betaAla-BBN(7-14)NH2 [(99m)Tc-HYNIC-BBN] and (99m)Tc identical withN(PNP6)-Cys-betaAla-BBN(7-14)NH2 [(99m)TcN(PNP6)-Cys-BBN] with regard to labeling procedures as well as in vitro and in vivo evaluation (biodistribution and scintigraphic imaging). METHODS Peptide synthesis was performed in an automated peptide synthesizer. HYNIC-BBN was radiolabeled with pertechnetate using tricine and ethylenediamine diacetic acid (EDDA) as coligands. Cys- BBN was radiolabeled in a two-step procedure with the preparation of the precursor (99m)Tc-Nitrido first and then introducing diphosphine (PNP6). Radiochemical evaluation of conjugates, as well as studies of stability, transchelation toward cysteine, and partition coefficient were done. Biological studies included internalization, biodistribution in healthy animals and in animals bearing PC3 cancer cells with acquisition of images from the tumor-bearing animals. RESULTS Both complexes showed a high radiochemical yield along with good stability. Biodistribution studies pointed out strong renal excretion for the former complex due to its hydrophilic profile and marked hepatobiliary excretion for the latter, corresponding to observed lipophilicity. Tumor uptake was higher for (99m)Tc-HYNIC-BBN and the same occurred with internalization findings, which exceeded those of (99m)TcN(PNP6)-BBN. Blocking studies in mice bearing PC-3 tumor cells revealed significantly reduced pancreas and tumor uptake, demonstrating receptor specificity of the conjugates. CONCLUSION The best radiotracer was (99m)Tc-HYNIC-BBN on the basis of high radiochemical yield, fast radiolabeling procedure without need for a purification step, and more consistent tumor uptake.
Collapse
Affiliation(s)
- Bluma Linkowski Faintuch
- Radiopharmacy Center, Institute of Energetic and Nuclear Research, Sao Paulo, SP 05508-000, Brazil.
| | | | | | | | | | | |
Collapse
|
41
|
Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 2008; 60:1347-70. [PMID: 18538888 PMCID: PMC2539110 DOI: 10.1016/j.addr.2008.04.006] [Citation(s) in RCA: 299] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2007] [Accepted: 04/16/2008] [Indexed: 11/23/2022]
Abstract
Receptor-based radiopharmaceuticals are of great current interest in molecular imaging and radiotherapy of cancers, and provide a unique tool for target-specific delivery of radionuclides to the diseased tissues. In general, a target-specific radiopharmaceutical can be divided into four parts: targeting biomolecule (BM), pharmacokinetic modifying (PKM) linker, bifunctional coupling or chelating agent (BFC), and radionuclide. The targeting biomolecule serves as a "carrier" for specific delivery of the radionuclide. PKM linkers are used to modify radiotracer excretion kinetics. BFC is needed for radiolabeling of biomolecules with a metallic radionuclide. Different radiometals have significant difference in their coordination chemistry, and require BFCs with different donor atoms and chelator frameworks. Since the radiometal chelate can have a significant impact on physical and biological properties of the target-specific radiopharmaceutical, its excretion kinetics can be altered by modifying the coordination environment with various chelators or coligand, if needed. This review will focus on the design of BFCs and their coordination chemistry with technetium, copper, gallium, indium, yttrium and lanthanide radiometals.
Collapse
Affiliation(s)
- Shuang Liu
- School of Health Sciences, Purdue University, West Lafayette, USA.
| |
Collapse
|
42
|
Lane SR, Veerendra B, Rold TL, Sieckman GL, Hoffman TJ, Jurisson SS, Smith CJ. 99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor. Nucl Med Biol 2008; 35:263-72. [PMID: 18355681 DOI: 10.1016/j.nucmedbio.2007.11.007] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2007] [Revised: 10/26/2007] [Accepted: 11/17/2007] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Targeted diagnosis of specific human cancer types continues to be of significant interest in nuclear medicine. 99mTc is ideally suited as a diagnostic radiometal for in vivo tumor targeting due to its ideal physical characteristics and diverse labeling chemistries in numerous oxidation states. METHODS In this study, we report a synthetic approach toward design of a new tridentate amine ligand for the organometallic aqua-ion [99mTc(H2O)3(CO)3]+. The new chelating ligand framework, 2-(N,N'-Bis(tert-butoxycarbonyl)diethylenetriamine) acetic acid (DTMA), was synthesized from a diethylenetriamine precursor and fully characterized by mass spectrometry and nuclear magnetic resonance spectroscopy (1H and 13C). DTMA was conjugated to H2N-(X)-BBN(7-14)NH2, where X=an amino acid or aliphatic pharmacokinetic modifier and BBN=bombesin peptide, by means of solid phase peptide synthesis. DTMA-(X)-BBN(7-14)NH2 conjugates were purified by reversed-phase high-performance chromatography and characterized by electrospray-ionization mass spectrometry. RESULTS The new conjugates were radiolabeled with [99mTc(H2O)3(CO)3]+ produced via Isolink radiolabeling kits to produce [99mTc(CO)3-DTMA-(X)-BBN(7-14)NH2]. Radiolabeled conjugates were purified by reversed-phase high-performance chromatography. Effective receptor binding behavior was evaluated in vitro and in vivo. CONCLUSIONS [99mTc(CO)3-DTMA-(X)-BBN(7-14)NH2] conjugates displayed very high affinity for the gastrin releasing peptide receptor in vitro and in vivo. Therefore, these conjugates hold some propensity to be investigated as molecular imaging agents that specifically target human cancers uniquely expressing the gastrin releasing peptide receptor subtypes.
Collapse
Affiliation(s)
- Stephanie R Lane
- Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
D'Andrea LD, Testa I, Panico M, Di Stasi R, Caracò C, Tarallo L, Arra C, Barbieri A, Romanelli A, Aloj L. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl. Biopolymers 2008; 90:707-12. [DOI: 10.1002/bip.21041] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Chiotellis A, Tsoukalas C, Pelecanou M, Raptopoulou C, Terzis A, Papadopoulos M, Papadopoulou-Daifoti Z, Pirmettis I. Convenient Route Leading to Neutral fac-M(CO)3(NNO) Complexes (M = Re, 99mTc) Coupled to Amine Pharmacophores. Inorg Chem 2008; 47:2601-7. [DOI: 10.1021/ic7019268] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Aris Chiotellis
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Charalambos Tsoukalas
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Maria Pelecanou
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Catherine Raptopoulou
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Aris Terzis
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Minas Papadopoulos
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Zetta Papadopoulou-Daifoti
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Ioannis Pirmettis
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| |
Collapse
|
45
|
de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP, de Jong M. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging 2007; 34:1228-38. [PMID: 17287960 DOI: 10.1007/s00259-006-0356-3] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2005] [Accepted: 12/03/2006] [Indexed: 12/25/2022]
Abstract
PURPOSE It has been shown that some primary human tumours and their metastases, including prostate and breast tumours, overexpress gastrin-releasing peptide (GRP) receptors. Bombesin (BN) is a neuropeptide with a high affinity for these GRP receptors. We demonstrated successful scintigraphic visualisation of BN receptor-positive tumours in preclinical studies using the radiolabelled BN analogue [(111)In-DTPA-Pro(1),Tyr(4)]BN. However, the receptor affinity as well as the serum stability of this analogue leave room for improvement. Therefore new (111)In-labelled BN analogues were synthesised and evaluated in vitro and in vivo. METHODS AND RESULTS The receptor affinity of the new BN analogues was tested on human GRP receptor-expressing prostate tumour xenografts and rat colon sections. Analogues with high receptor affinity (low nM range) were selected for further evaluation. Incubation in vitro of GRP receptor-expressing rat CA20948 and human PC3 tumour cells with the (111)In-labelled analogues resulted in rapid receptor-mediated uptake and internalisation. The BN analogue with the best receptor affinity and in vitro internalisation characteristics, Cmp 3 ([(111)In-DTPA-ACMpip(5),Tha(6),betaAla(11),Tha(13),Nle(14)]BN(5-14)), was tested in vivo in biodistribution studies using rats bearing GRP receptor-expressing CA20948 tumours, and nude mice bearing human PC3 xenografts. Injection of (111)In-labelled Cmp 3 in these animals showed high, receptor-mediated uptake in receptor-positive organs and tumours which could be visualised using planar gamma camera and microSPECT/CT imaging. CONCLUSION With their enhanced receptor affinity and their rapid receptor-mediated internalisation in vitro and in vivo, the new BN analogues, and especially Cmp 3, are promising candidates for use in diagnostic molecular imaging and targeted radionuclide therapy of GRP receptor-expressing cancers.
Collapse
Affiliation(s)
- M de Visser
- Department of Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Ma L, Yu P, Veerendra B, Rold TL, Retzloff L, Prasanphanich A, Sieckman G, Hoffman TJ, Volkert WA, Smith CJ. In Vitro and In Vivo Evaluation of Alexa Fluor 680-Bombesin[7–14]NH2Peptide Conjugate, a High-Affinity Fluorescent Probe with High Selectivity for the Gastrin-Releasing Peptide Receptor. Mol Imaging 2007. [DOI: 10.2310/7290.2007.00013] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Lixin Ma
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Ping Yu
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Bhadrasetty Veerendra
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Tammy L. Rold
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Lauren Retzloff
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Adam Prasanphanich
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Gary Sieckman
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Timothy J. Hoffman
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Wynn A. Volkert
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| | - Charles J. Smith
- From the Departments of Radiology, Internal Medicine, and Medical Pharmacology and Physiology; The Radiopharmaceutical Sciences Institute; and International Institute of Nano and Molecular Medicine, University of Missouri-Columbia School of Medicine; Department of Physics and Astronomy, University of Missouri-Columbia; University of Missouri Research Reactor Center, University of Missouri-Columbia; and Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO
| |
Collapse
|
47
|
He Z, Hsieh WY, Kim YS, Liu S. Evaluation of novel cationic 99mTc(I)-tricarbonyl complexes as potential radiotracers for myocardial perfusion imaging. Nucl Med Biol 2007; 33:1045-53. [PMID: 17127179 DOI: 10.1016/j.nucmedbio.2006.08.009] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2006] [Revised: 08/08/2006] [Accepted: 08/29/2006] [Indexed: 11/30/2022]
Abstract
This report describes the evaluation of three cationic (99m)Tc(I)-tricarbonyl complexes--[(99m)Tc(CO)(3)(L)](+) (L=N-methoxyethyl-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (ME-PNP), N-[15-crown-5)-2-yl]-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (15C5-PNP) and N-[18-crown-6)-2-yl]-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (18C6-PNP))--as potential radiotracers for myocardial perfusion imaging. Biodistribution, imaging and metabolism studies were performed using Sprague-Dawley rats. It was found that bisphosphine ligands have a significant impact on the biodistribution characteristics and clearance kinetics of their cationic (99m)Tc(I)-tricarbonyl complexes. Among the three radiotracers evaluated in this study, [(99m)Tc(CO)(3)(15C5-PNP)](+) has a very high initial heart uptake and is retained in the rat myocardium for >2 h. It also shows rapid clearance from the liver and lungs. The heart/liver ratio of [(99m)Tc(CO)(3)(15C5-PNP)](+) is approximately 2.5 times better than that of (99m)Tc-sestamibi at 30 min postinjection. [(99m)Tc(CO)(3)(15C5-PNP)](+) is almost identical to (99m)TcN-DBODC5 with respect to heart uptake, heart/lung ratio and heart/liver ratio. Results from metabolism studies show that there is no significant metabolism for [(99m)Tc(CO)(3)(15C5-PNP)](+) in the urine, but it does show a small metabolite peak (<10%) in the radio high-performance liquid chromatography chromatogram of the feces sample at 120 min postinjection. Results planar imaging studies demonstrate that [(99m)Tc(CO)(3)(15C5-PNP)](+) has a much better liver clearance profile than (99m)Tc-sestamibi and might give clinically useful images of the heart as early as 30 min postinjection. [(99m)Tc(CO)(3)(15C5-PNP)](+) is a very promising candidate for more preclinical evaluations in various animal models.
Collapse
Affiliation(s)
- Zhengjie He
- School of Health Sciences, Purdue University, West Lafayette, IN 47907-2051, USA
| | | | | | | |
Collapse
|
48
|
Veerendra B, Sieckman GL, Hoffman TJ, Rold T, Retzloff L, McCrate J, Prasanphanich A, Smith CJ. Synthesis, Radiolabeling and In vitro GRP Receptor Targeting Studies of 99mTc‐Triaza‐X‐BBN[7‐14]NH2 (X=Serylserylserine, Glycylglycylglycine, Glycylserylglycine, or Beta Alanine). ACTA ACUST UNITED AC 2007. [DOI: 10.1080/15533170600778075] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Bhadrasetty Veerendra
- a Department of Radiology , University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
| | - Gary L. Sieckman
- c Research Division, Harry S. Truman Memorial Veterans' Hospital , Columbia, Missouri, USA
| | - Timothy J. Hoffman
- c Research Division, Harry S. Truman Memorial Veterans' Hospital , Columbia, Missouri, USA
- d Department of Internal Medicine, University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
| | - Tammy Rold
- d Department of Internal Medicine, University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
| | - Lauren Retzloff
- a Department of Radiology , University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
| | - Joseph McCrate
- a Department of Radiology , University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
| | - Adam Prasanphanich
- a Department of Radiology , University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
| | - Charles J. Smith
- a Department of Radiology , University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
- b University of Missouri Research Reactor Center , University of Missouri‐Columbia , Columbia, Missouri, USA
- c Research Division, Harry S. Truman Memorial Veterans' Hospital , Columbia, Missouri, USA
- d Department of Internal Medicine, University of Missouri‐Columbia School of Medicine , Columbia, Missouri, USA
| |
Collapse
|
49
|
Faintuch BL, Santos RLSR, Souza ALFM, Hoffman TJ, Greeley M, Smith CJ. 99mTc‐HYNIC‐Bombesin (7‐14)NH2: Radiochemical Evaluation with Co‐ligands EDDA (EDDA = Ethylenediamine‐N,N′‐diacetic Acid), Tricine, and Nicotinic Acid. ACTA ACUST UNITED AC 2007. [DOI: 10.1081/sim-200047545] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- B. L. Faintuch
- a Radiopharmacy Center , Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN) , São Paulo, SP, Brazil
| | - R. L. S. R. Santos
- a Radiopharmacy Center , Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN) , São Paulo, SP, Brazil
| | - A. L. F. M. Souza
- a Radiopharmacy Center , Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN) , São Paulo, SP, Brazil
| | - T. J. Hoffman
- b Research Services, Harry S. Truman Memorial Veterans' Hospital , Columbia, MO, USA
- c Department of Internal Medicine , University of Missouri‐Columbia School of Medicine , Columbia, MO, USA
| | - M. Greeley
- c Department of Internal Medicine , University of Missouri‐Columbia School of Medicine , Columbia, MO, USA
| | - C. J. Smith
- b Research Services, Harry S. Truman Memorial Veterans' Hospital , Columbia, MO, USA
- d Dept. of Radiology , University of Missouri‐Columbia School of Medicine , Columbia, MO, USA
- e University of Missouri‐Columbia Research Reactor Center , Columbia, MO, USA
| |
Collapse
|
50
|
Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007; 34:1198-208. [PMID: 17262215 DOI: 10.1007/s00259-006-0347-4] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2006] [Accepted: 11/17/2006] [Indexed: 10/23/2022]
Abstract
PURPOSE We aimed at designing and developing a novel bombesin analogue, DOTA-PEG(4)-BN(7-14) (DOTA-PESIN), with the goal of labelling it with (67/68)Ga and (177)Lu for diagnosis and radionuclide therapy of prostate and other human cancers overexpressing bombesin receptors. METHODS The 8-amino acid peptide bombesin (7-14) was coupled to the macrocyclic chelator DOTA via the spacer 15-amino-4,7,10,13-tetraoxapentadecanoic acid (PEG(4)). The conjugate was complexed with Ga(III) and Lu(III) salts. The GRP receptor affinity and the bombesin receptor subtype profile were determined in human tumour specimens expressing the three bombesin receptor subtypes. Internalisation and efflux studies were performed with the human GRP receptor cell line PC-3. Xenografted nude mice were used for biodistribution. RESULTS [Ga(III)/Lu(III)]-DOTA-PESIN showed good affinity to GRP and neuromedin B receptors but no affinity to BB3. [(67)Ga/(177)Lu]-DOTA-PESIN internalised rapidly into PC-3 cells whereas the efflux from PC-3 cells was relatively slow. In vivo experiments showed a high and specific tumour uptake and good retention of [(67)Ga/(177)Lu]-DOTA-PESIN. [(67)Ga/(177)Lu]-DOTA-PESIN highly accumulated in GRP receptor-expressing mouse pancreas. The uptake specificity was demonstrated by blocking tumour uptake and pancreas uptake. Fast clearance was found from blood and all non-target organs except the kidneys. High tumour-to-normal tissue ratios were achieved, which increased with time. PET imaging with [(68)Ga]-DOTA-PESIN was successful in visualising the tumour at 1 h post injection. Planar scintigraphic imaging showed that the (177)Lu-labelled peptide remained in the tumour even 3 days post injection. CONCLUSION The newly designed ligands have high potential with regard to PET and SPECT imaging with (68/67)Ga and targeted radionuclide therapy with (177)Lu.
Collapse
Affiliation(s)
- Hanwen Zhang
- Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
| | | | | | | | | | | | | |
Collapse
|